Teachers Retirement System of The State of Kentucky Raises Stock Holdings in United Therapeutics Corporation $UTHR

Teachers Retirement System of The State of Kentucky increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 8.9% in the first quarter, Holdings Channel.com reports. The fund owned 33,624 shares of the biotechnology company’s stock after buying an additional 2,760 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in United Therapeutics were worth $19,937,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of UTHR. Avoro Capital Advisors LLC lifted its position in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC increased its stake in United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after buying an additional 295,221 shares during the period. Janus Henderson Group PLC increased its stake in United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares during the period. Finally, Darwin Global Management Ltd. bought a new stake in United Therapeutics during the 3rd quarter valued at about $317,617,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $577.18, for a total value of $5,771,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,894,849.68. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 593,543 shares of company stock worth $333,556,328 over the last 90 days. Company insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on UTHR. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday. Finally, Royal Bank Of Canada increased their price objective on United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $644.82.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $535.57 on Tuesday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm’s 50-day moving average is $555.98 and its two-hundred day moving average is $529.73. The stock has a market cap of $22.73 billion, a price-to-earnings ratio of 19.77, a PEG ratio of 1.80 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the prior year, the firm posted $6.63 EPS. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, equities analysts expect that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.